<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The endocannabinoids <z:chebi fb="0" ids="2700">anandamide</z:chebi> (AEA) and palmitoylethanolamide (PEA) act as endogenous protective factors of the brain, using different pathways of neuroprotection against neuronal damage </plain></SENT>
<SENT sid="1" pm="."><plain>Although several in vivo and in vitro studies confirmed the neuroprotective efficacy of endocannabinoids, no experimental settings compare and explore the neuroprotective potential of AEA and PEA in an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the neuroprotective potential by <z:mpath ids='MPATH_124'>infarct</z:mpath> measurement after high (30 mg/kg body weight) and low dosage administration (10 mg/kg body weight) of the endocannabinoid PEA in 49 male Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain>In additions we studied <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes of 22 male Wistar rats receiving the endocannabinoid AEA with a dosage of 10 mg/kg body weight or placebo </plain></SENT>
<SENT sid="4" pm="."><plain>The neurological outcome was assessed 24 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Endocannabinoids were given intraperitoneally 30 min after initiation of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAO) </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume was calculated on the basis of 2.3.5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining </plain></SENT>
<SENT sid="7" pm="."><plain>In the PEA high-dose group a significant total <z:mpath ids='MPATH_124'>infarct</z:mpath> reduction of 35% compared to the control group could be observed </plain></SENT>
<SENT sid="8" pm="."><plain>AEA-treated rats presented a total <z:mpath ids='MPATH_124'>infarct</z:mpath> reducing effect of 26% compared to controls </plain></SENT>
<SENT sid="9" pm="."><plain>Neurological scores, evaluated 24 h after tMCAO and physiological parameters, obtained 45 and 90 min after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> showed no significant differences among the groups </plain></SENT>
<SENT sid="10" pm="."><plain>As shown here, the endocannabinoids AEA and PEA achieved a significant neuroprotective effect by reducing size of infarcted tissue after tMCAO </plain></SENT>
<SENT sid="11" pm="."><plain>Both endocannabinoids may have the potential to treat <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> and exert neuroprotection through a variety of mechanisms </plain></SENT>
</text></document>